Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (29)
Alessandro Massano, Luisa Bertin, Fabiana Zingone, Andrea Buda, Pierfrancesco Visaggi, Lorenzo Bertani, Nicola de Bortoli, Matteo Fassan, Marco Scarpa, Cesare Ruffolo, Imerio Angriman, Cristina Bezzio, Valentina Casini, Davide Giuseppe Ribaldone, Edoardo Vincenzo Savarino & Brigida Barberio. (2023) Extraintestinal Cancers in Inflammatory Bowel Disease: A Literature Review. Cancers 15:15, pages 3824.
Crossref
Crossref
Aldukhayel Abdulrhman, Adil Alsweed, May Rashed Alotaibi, Abdullah Yousef Aldakhil, Shahad Fahad Alahmadi, Saud Musallum Albishri & Nurah Ibrahem Alhmed. (2023) Urolithiasis in patients with inflammatory bowel disease: A systematic review and meta-analysis of 13,339,065 individuals. Medicine 102:24, pages e33938.
Crossref
Crossref
Edward V LoftusJrJr, Daniel C Baumgart, Krisztina Gecse, Jami A Kinnucan, Susan B Connelly, Leonardo Salese, Chinyu Su, Kenneth K Kwok, John C Woolcott & Alessandro Armuzzi. (2023)
Clostridium difficile
Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program
. Inflammatory Bowel Diseases 29:5, pages 744-751.
Crossref
Crossref
Irēna Teterina, Viktorija Mokricka, Eva Petrošina & Juris Pokrotnieks. (2022) Burden of extraintestinal manifestations and comorbidities in treated and untreated ulcerative colitis and Crohn’s disease: a Latvian nationwide prescription database study 2014–2019. Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. 76:5-6, pages 608-617.
Crossref
Crossref
Kanya K ShahAisling R CaffreyAndy SzczotkaDea BelaziStephen J Kogut. (2022) Real-world utilization of top-down and step-up therapy and initial costs in Crohn disease. Journal of Managed Care & Specialty Pharmacy 28:8, pages 849-861.
Crossref
Crossref
Alina Ecaterina Jucan, Otilia Gavrilescu, Mihaela Dranga, Iolanda Valentina Popa, Bogdan Mircea Mihai, Cristina Cijevschi Prelipcean & Cătălina Mihai. (2022) Ischemic Heart Disease in Patients with Inflammatory Bowel Disease: Risk Factors, Mechanisms and Prevention. Life 12:8, pages 1113.
Crossref
Crossref
Eleftheria E. Kampouri, Jonathan Tschopp & Oriol Manuel. 2022. Infectious Complications in Biologic and Targeted Therapies. Infectious Complications in Biologic and Targeted Therapies
253
272
.
Jeffrey R Curtis, Miguel Regueiro, Huifeng Yun, Chinyu Su, Marco DiBonaventura, Nervin Lawendy, Chudy I Nduaka, Nana Koram, Joseph C Cappelleri, Gary Chan, Irene Modesto & Gary R Lichtenstein. (2021) Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data. Inflammatory Bowel Diseases 27:9, pages 1394-1408.
Crossref
Crossref
Celeste Witting, Craig B. Langman, Dean Assimos, Michelle A. Baum, Annamaria Kausz, Dawn Milliner, Greg Tasian, Elaine Worcester, Meaghan Allain, Melissa West, Felix Knauf & John C. Lieske. (2021) Pathophysiology and Treatment of Enteric Hyperoxaluria. Clinical Journal of the American Society of Nephrology 16:3, pages 487-495.
Crossref
Crossref
Zhihui Li, Lili Qiao, Xiaojing Yun, Fangjuan Du, Shilei Xing & Maowu Yang. (2020) Increased risk of ischemic heart disease and diabetes in inflammatory bowel disease. Zeitschrift für Gastroenterologie 59:02, pages 117-124.
Crossref
Crossref
Edward V. LoftusJrJr, Brian G. Feagan, Remo Panaccione, Jean-Frédéric Colombel, William J. Sandborn, Bruce E. Sands, Silvio Danese, Geert D’Haens, David T. Rubin, Ira Shafran, Andrejus Parfionovas, Raquel Rogers, Richard A. Lirio & Séverine Vermeire. (2020) Long-term safety of vedolizumab for inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 52:8, pages 1353-1365.
Crossref
Crossref
Bálint Tél, Bence Stubnya, Noémi Gede, Péter Varjú, Zoltán Kiss, Katalin Márta, Péter Jenő Hegyi, András Garami, Eszter Hegyi, Zsolt Szakács, Péter Hegyi & Gábor Veres. (2020) Inflammatory Bowel Diseases Elevate the Risk of Developing Acute Pancreatitis. Pancreas 49:9, pages 1174-1181.
Crossref
Crossref
Shamarke Esse, Kayleigh J. Mason, Adele C. Green & Richard B. Warren. (2020) Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases. JAMA Dermatology 156:7, pages 787.
Crossref
Crossref
Alain Bitton, Katharine S Devitt, Brian Bressler, Joan Heatherington, Vipul Jairath, Jennifer Jones, Paul Moayyedi, Adam V Weizman, Catherine Dubé, Donald MacIntosh & Geoffrey C Nguyen. (2020) Development of a Global Rating Scale for Inflammatory Bowel Disease. Journal of the Canadian Association of Gastroenterology 3:1, pages 4-16.
Crossref
Crossref
Thomas Wilke, Antje Groth, Gráinne H. Long, Amanda R. Tatro & Diana Sun. (2020) Rate of Adverse Events and Associated Health Care Costs for the Management of Inflammatory Bowel Disease in Germany. Clinical Therapeutics 42:1, pages 130-143.e3.
Crossref
Crossref
Gráinne H. Long, Amanda R. Tatro, Young S. Oh, Sheila R. Reddy & Ashwin N. Ananthakrishnan. (2019) Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data. Advances in Therapy 36:11, pages 3079-3095.
Crossref
Crossref
Yoon Jin Choi, Dong Ho Lee, Dong Woo Shin, Kyung-Do Han, Hyuk Yoon, Cheol Min Shin, Young Soo Park & Nayoung Kim. (2019) Patients with inflammatory bowel disease have an increased risk of myocardial infarction: a nationwide study. Alimentary Pharmacology & Therapeutics 50:7, pages 769-779.
Crossref
Crossref
Qiong He. (2019) Cardiocerebral and peripheral vascular risks in inflammatory bowel disease. World Chinese Journal of Digestology 27:5, pages 341-346.
Crossref
Crossref
Yizhou Ye, Sudhakar Manne & Dimitri Bennett. (2019) Identifying Patients With Inflammatory Bowel Diseases in an Administrative Health Claims Database: Do Algorithms Generate Similar Findings?. INQUIRY: The Journal of Health Care Organization, Provision, and Financing 56, pages 004695801988781.
Crossref
Crossref
Natalie E Mitchell, Nicole Harrison, Zachary Junga & Manish Singla. (2018) Heart Under Attack: Cardiac Manifestations of Inflammatory Bowel Disease. Inflammatory Bowel Diseases 24:11, pages 2322-2326.
Crossref
Crossref
Siew C Ng, Ida Normiha Hilmi, Aimee Blake, Fatima Bhayat, Shashi Adsul, Qasim Rana Khan & Deng-Chyang Wu. (2018) Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting. Inflammatory Bowel Diseases 24:11, pages 2431-2441.
Crossref
Crossref
Brian G Feagan, Fatima Bhayat, Mona Khalid, Aimee Blake & Simon P L Travis. (2018) Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials. Journal of Crohn's and Colitis 12:8, pages 905-919.
Crossref
Crossref
George A. Stamatiades, Petros Ioannou, George Petrikkos & Constantinos Tsioutis. (2018) Fungal infections in patients with inflammatory bowel disease: A systematic review. Mycoses 61:6, pages 366-376.
Crossref
Crossref
M. T. Tang, M. E. Keir, R. Erickson, E. G. Stefanich, F. K. Fuh, T. Ramirez-Montagut, J. M. McBride & D. M. Danilenko. (2018) Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 47:11, pages 1440-1452.
Crossref
Crossref
Sung Chul Park & Yoon Tae Jeen. (2018) Anti-integrin therapy for inflammatory bowel disease. World Journal of Gastroenterology 24:17, pages 1868-1880.
Crossref
Crossref
Geom Seog SeoSung Hee Lee. (2018) Emerging Therapies: What Are Promising in the Near Future?. The Korean Journal of Gastroenterology 71:2, pages 81.
Crossref
Crossref
Wan Feng, Guangxia Chen, Dawei Cai, Song Zhao, Jiafei Cheng & Hong Shen. (2017) Inflammatory Bowel Disease and Risk of Ischemic Heart Disease: An Updated Meta‐Analysis of Cohort Studies. Journal of the American Heart Association 6:8.
Crossref
Crossref
Jean-Frédéric Colombel, Bruce E Sands, Paul Rutgeerts, William Sandborn, Silvio Danese, Geert D'Haens, Remo Panaccione, Edward V LoftusJrJr, Serap Sankoh, Irving Fox, Asit Parikh, Catherine Milch, Brihad Abhyankar & Brian G Feagan. (2017) The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 66:5, pages 839-851.
Crossref
Crossref
Vijay Yajnik, Nabeel Khan, Marla Dubinsky, Jeffrey Axler, Alexandra James, Brihad Abhyankar & Karen Lasch. (2017) Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age. Advances in Therapy 34:2, pages 542-559.
Crossref
Crossref